AU2016208475B2 - Universal killer T-cell - Google Patents

Universal killer T-cell Download PDF

Info

Publication number
AU2016208475B2
AU2016208475B2 AU2016208475A AU2016208475A AU2016208475B2 AU 2016208475 B2 AU2016208475 B2 AU 2016208475B2 AU 2016208475 A AU2016208475 A AU 2016208475A AU 2016208475 A AU2016208475 A AU 2016208475A AU 2016208475 B2 AU2016208475 B2 AU 2016208475B2
Authority
AU
Australia
Prior art keywords
cell
cells
tcr
modified
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016208475A
Other languages
English (en)
Other versions
AU2016208475A1 (en
Inventor
Gustav Gaudernack
Gunnar Kvalheim
Else Marit Inderberg Suso
Sébastien WÄLCHLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oslo Universitetssykehus hf
Original Assignee
Oslo Universitetssykehus hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oslo Universitetssykehus hf filed Critical Oslo Universitetssykehus hf
Publication of AU2016208475A1 publication Critical patent/AU2016208475A1/en
Application granted granted Critical
Publication of AU2016208475B2 publication Critical patent/AU2016208475B2/en
Priority to AU2022200126A priority Critical patent/AU2022200126A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2016208475A 2015-01-23 2016-01-22 Universal killer T-cell Active AU2016208475B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022200126A AU2022200126A1 (en) 2015-01-23 2022-01-11 Universal killer T-cell

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1501175.2 2015-01-23
GBGB1501175.2A GB201501175D0 (en) 2015-01-23 2015-01-23 A universal T-cell for personalised medicine
PCT/EP2016/051344 WO2016116601A1 (en) 2015-01-23 2016-01-22 Universal killer t-cell

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200126A Division AU2022200126A1 (en) 2015-01-23 2022-01-11 Universal killer T-cell

Publications (2)

Publication Number Publication Date
AU2016208475A1 AU2016208475A1 (en) 2017-08-03
AU2016208475B2 true AU2016208475B2 (en) 2021-10-14

Family

ID=52673865

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016208475A Active AU2016208475B2 (en) 2015-01-23 2016-01-22 Universal killer T-cell
AU2022200126A Abandoned AU2022200126A1 (en) 2015-01-23 2022-01-11 Universal killer T-cell

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022200126A Abandoned AU2022200126A1 (en) 2015-01-23 2022-01-11 Universal killer T-cell

Country Status (17)

Country Link
US (2) US11155786B2 (enExample)
EP (3) EP4681735A3 (enExample)
JP (1) JP6899333B2 (enExample)
KR (1) KR102479118B1 (enExample)
CN (1) CN107250351A (enExample)
AU (2) AU2016208475B2 (enExample)
CA (1) CA2973924C (enExample)
DK (1) DK3247791T3 (enExample)
EA (1) EA201791381A1 (enExample)
ES (1) ES2922231T3 (enExample)
GB (1) GB201501175D0 (enExample)
IL (1) IL253464B (enExample)
MX (1) MX390756B (enExample)
PL (1) PL3247791T3 (enExample)
PT (1) PT3247791T (enExample)
SG (1) SG11201705693XA (enExample)
WO (1) WO2016116601A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
BR112017024757A2 (pt) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr utilizando proteínas de fusão
WO2017192440A1 (en) * 2016-05-02 2017-11-09 Cerus Corporation Compositions and methods for improved nk cell therapies
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US20190358263A1 (en) 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
US11752172B2 (en) 2017-01-04 2023-09-12 Nova Southeastern University Natural killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex, methods for production thereof, and methods for therapeutic use thereof
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
CN112912727A (zh) * 2018-08-31 2021-06-04 因维克蒂斯股份有限公司 评估car功能性的方法
WO2020191358A1 (en) * 2019-03-20 2020-09-24 Bluebird Bio, Inc. Adoptive cell therapy
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
EP3750547A1 (en) * 2019-06-13 2020-12-16 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Modified nk-92 cells, and therapeutic and diagnostic uses thereof
WO2021021930A1 (en) 2019-07-29 2021-02-04 Massachusetts Institute Of Technology Synthetic hydrogels for organogenesis
CN111662871A (zh) * 2020-06-11 2020-09-15 福建医科大学孟超肝胆医院(福州市传染病医院) 一种核酸适体功能化nk细胞及其制备与应用
BR112023005318A2 (pt) 2020-09-24 2023-04-25 Medigene Immunotherapies Gmbh Receptores de célula t específicos de prame e uso dos mesmos
WO2022095902A1 (en) * 2020-11-03 2022-05-12 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
GB202017873D0 (en) 2020-11-12 2020-12-30 Olso Unversitetssykehus Hf Method of determining DLBCL prognosis
KR20220160479A (ko) * 2021-05-27 2022-12-06 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포
EP4404956B1 (en) 2021-09-21 2026-04-01 Oslo Universitetssykehus HF Binding proteins for terminal deoxynucleotidyl transferase (tdt)
WO2023078287A1 (en) * 2021-11-03 2023-05-11 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
WO2024020537A2 (en) * 2022-07-22 2024-01-25 Board Of Regents, The University Of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
CN121358493A (zh) 2023-06-20 2026-01-16 泽卢纳免疫疗法公司 增强或修饰nk细胞的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124251A (en) 1990-01-31 1992-06-23 Becton, Dickinson And Company CD3 ζ co-associated complex on CD16- NK cells
EP1690927A1 (en) 1997-04-30 2006-08-16 Hans Klingemann Natural killer cell lines and methods of use
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
AU2002351239A1 (en) 2001-12-04 2003-06-17 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof
PL2921500T3 (pl) * 2004-07-10 2024-02-05 The Institute For Cancer Research Genetycznie zmodyfikowane ludzkie linie komórkowe naturalni zabójcy
EP1809738B1 (en) * 2004-11-02 2014-03-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Compositions and methods for treating hyperproliferative disorders
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
CN101631138A (zh) 2008-07-18 2010-01-20 深圳富泰宏精密工业有限公司 个人信息代理系统及方法
WO2010088160A1 (en) * 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2013126785A1 (en) * 2012-02-22 2013-08-29 Ingenium Biotherapy Corporation A system for immunotherapy targeting tumor propagation and progression
ES2871349T3 (es) 2012-09-04 2021-10-28 Inven2 As Expansión selectiva y controlada de células NK educadas
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
CN105378078B (zh) 2013-02-04 2019-03-01 罗杰威廉姆斯医疗中心 用于治疗胃肠道间质瘤(gist)的方法和组合物
JP6425301B2 (ja) 2014-05-29 2018-11-21 国立大学法人富山大学 Ｔｃｒの細胞傷害活性誘導能を評価するためのｎｋ細胞株、およびその作製方法
CN106459916A (zh) 2014-06-18 2017-02-22 乔治-施派尔-豪斯化学疗法研究所 作为细胞治疗剂的car‑表达nk‑92细胞
US20170274014A1 (en) * 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVID A. KNORR et al., "Pluripotent stem cell-derived natural killer cells for cancer therapy", Translational Research, 2010, vol. 156, no. 3, pages 147-154. *
Lanier, L et al., Journal of Immunology, 1992, vol. 149, no. 6, pp. 1876-1880. *
PATTERSON, S. et al. 'Human Invariant NKT cells Display Alloreactivity Instructed by Invariant TCR-CD1d Interaction and Killer Ig Receptors.' The Journal of Immunology, 2008, vol. 181, pages 3268-3276. *
V. RENARD ET AL, "Normal development and function of natural killer cells in CD3 epsilon delta 5/delta 5 mutant mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (1995-08-01), vol. 92, no. 16, pages 7545 - 7549 *

Also Published As

Publication number Publication date
EP4681735A3 (en) 2026-03-25
EP3247791B1 (en) 2022-05-04
EA201791381A1 (ru) 2018-02-28
PL3247791T3 (pl) 2022-09-05
SG11201705693XA (en) 2017-08-30
NZ733855A (en) 2023-10-27
EP4095239A1 (en) 2022-11-30
CA2973924C (en) 2024-06-04
US20220127574A1 (en) 2022-04-28
BR112017015631A2 (pt) 2018-03-13
ES2922231T3 (es) 2022-09-12
US20180010097A1 (en) 2018-01-11
KR20170121178A (ko) 2017-11-01
US11155786B2 (en) 2021-10-26
MX390756B (es) 2025-03-04
WO2016116601A1 (en) 2016-07-28
GB201501175D0 (en) 2015-03-11
KR102479118B1 (ko) 2022-12-16
IL253464A0 (en) 2017-09-28
AU2022200126A1 (en) 2022-02-10
MX2017009459A (es) 2018-04-11
IL253464B (en) 2022-04-01
JP2018512047A (ja) 2018-05-10
PT3247791T (pt) 2022-07-20
CN107250351A (zh) 2017-10-13
CA2973924A1 (en) 2016-07-28
JP6899333B2 (ja) 2021-07-07
EP3247791A1 (en) 2017-11-29
EP4681735A2 (en) 2026-01-21
AU2016208475A1 (en) 2017-08-03
DK3247791T3 (da) 2022-07-11

Similar Documents

Publication Publication Date Title
US20220127574A1 (en) Universal Killer T-Cell
TWI914666B (zh) 源自液體腫瘤之腫瘤浸潤性淋巴細胞的擴增和該經擴增腫瘤浸潤性淋巴細胞之治療用途
RU2739770C2 (ru) Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
JP6884155B2 (ja) 癌治療のための併用免疫療法及びサイトカイン制御療法
JP6858128B2 (ja) 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
Miller et al. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy
CN105848484A (zh) 用于免疫治疗的多克隆γδ T细胞
KR20090127973A (ko) 자기활성화 림프구 배양 방법
TW202039540A (zh) 一種治療ｅｂｖ相關性癌症之抗ｌｍｐ２ ｔｃｒ-ｔ細胞療法
JP2022500038A (ja) 癌免疫療法用ｍｒ１制限ｔ細胞受容体
JP6687246B2 (ja) 改変型免疫細胞、改変型免疫細胞の製造方法、およびこれらの利用
Balza et al. The therapeutic T‐cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells
WO2022214089A1 (zh) 细胞免疫治疗的应用
HK1240267B (en) Universal killer t-cell
HK1240267A1 (en) Universal killer t-cell
NZ733855B2 (en) Universal killer t-cell
CN104761636B (zh) 一种HLA-A33限制性eEF2表位多肽及其应用
EA040420B1 (ru) Универсальная клетка т-киллер
Janelle et al. T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies. Cancers 2021, 13, 598
CA2951749C (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
WO2026074195A1 (en) Cytokine loaded activated dendritic cells
BR112017015631B1 (pt) Uso de uma célula nk modificada, composição terapêutica, métodos para a produção de uma célula nk universal e para preparar uma célula nk modificada e kit